Pharvaris Announces Statistically Significant And Clinically Meaningful Topline Results From Its CHAPTER-3 Pivotal Phase 3 Study Evaluating Deucrictibant Extended-Release Tablet For Prevention Of HAE Attacks; Primary Endpoint And All Secondary Efficacy Endpoints Were Met With Statistical Significance
Benzinga Newsdesk 1 month ago
FDANews
Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE87% attack rate reduction versus placebo observed in people with HAE
- Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE
- 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2
- All secondary efficacy endpoints met with statistical significance
- Well-tolerated safety profile of deucrictibant XR demonstrated
- Conference call and webcast today at 8:00 a.m. EDT